Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857345 | 0.82 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL8643701 | 0.80 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL11928239 | 0.77 | — | — | |
| SCHEMBL11928241 | 0.77 | — | — | |
| SCHEMBL2371656 | 0.77 | — | — | |
| SCHEMBL24088389 | 0.77 | — | — | |
| SCHEMBL27990631 | 0.77 | ALDH1A1 (0.37) | LMNAADRB3FDPSPDE4DPDE3A | |
| SCHEMBL27997338 | 0.76 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL22149845 | 0.74 | ALDH1A1 (0.59) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2371628 | 0.74 | CYP2D6 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630404-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121048-A1 | UREA COMPOUNDS AS ACTIVATORS OF POTASSIUM CHANNELS KV7.2/7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| US-7671080-B2 | 1-benzylindole-2-carboxamide derivatives | N.V. ORGANON (NL) | 2010-03-02 | — | — | US | disclosed |
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | N.V. ORGANON (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1940788-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. Organon (NL) | 2008-07-09 | — | — | EP | disclosed |
| WO-2006100208-A9 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | ORGANON NV (NL) | 2007-11-22 | — | — | WO | disclosed |
| WO-2006100208-A1 | 1-BENZYLINDOLE-2-CARBOXAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280923-A1 | 1-Benzylindole-2-Carboxamide Derivatives | CNR2, CNR1, HTR2C | LMNA 3622/4885ADRB3 118/4885FDPS 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.